LXJ-02

LXJ-02 is a preclinical-stage ultralong-acting peptide inhibitor developed by Shenzhen Turier Biotech for the treatment of pulmonary fibrosis. It specifically targets the elastin-binding protein (EBP), disrupting the interaction between EBP and elastin-derived peptides (EDPs). This disruption activates the macrophage-MMP-12 axis, leading to the increased secretion of matrix metalloproteinase-12 (MMP-12), an enzyme that degrades extracellular matrix (ECM) components such as elastin. By promoting the degradation of the ECM, LXJ-02 aims to reverse the pathological remodeling characteristic of pulmonary fibrosis. The drug has demonstrated efficacy in mouse models of the disease with a favorable safety profile.